Moxifloxacin Aurovitas (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Aurovitas, is a fluoroquinolone antibiotic presented as an oral dosage form for oral use. It is employed to treat a range of serious bacterial infections in adult patients, including respiratory, sinus, skin and intra‑abdominal infections.

GNH USA supplies Moxifloxacin Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions and ensures timely delivery.

Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory, sinus, skin and intra‑abdominal systems. Community‑acquired bacterial pneumonia: achieves bacterial eradication and clinical cure in adult patients. Acute bacterial sinusitis: reduces symptoms and promotes rapid resolution of infection. Acute bacterial exacerbation of chronic bronchitis: improves lung function and shortens disease course. Skin and skin structure infections: eliminates causative pathogens and supports wound healing. Intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

Moxifloxacin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset occurring in many patients. - Diarrhea: loose stools that are usually self‑limiting. - Headache: transient cranial discomfort reported during therapy.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially of the Achilles tendon. - QT interval prolongation: risk of cardiac arrhythmias, particularly in patients with pre‑existing heart conditions. - Severe allergic reactions: including anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

When prescribing Moxifloxacin, clinicians should observe several precautionary measures to minimize risk. Assess renal function: adjust therapy in patients with impaired clearance. Monitor for tendon pain: discontinue if signs of tendinopathy appear. Avoid concurrent use with antacids containing aluminum, magnesium, calcium, iron, or zinc: these may reduce drug absorption. Use with caution in patients at risk of QT prolongation: consider ECG monitoring. Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of tendon rupture. - Other fluoroquinolones: additive toxicity and overlapping adverse effects. - Drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antacids or supplements containing calcium, iron, zinc, or magnesium: may decrease absorption; separate dosing by at least two hours. - Warfarin: potential enhancement of anticoagulant effect; monitor INR. - Theophylline: possible increase in serum levels; observe for signs of toxicity.